Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
0.6417
-0.0204 (-3.08%)
At close: Feb 4, 2026, 4:00 PM EST
0.6289
-0.0128 (-1.99%)
After-hours: Feb 4, 2026, 7:57 PM EST
Werewolf Therapeutics Employees
Werewolf Therapeutics had 39 employees as of September 30, 2025. The number of employees decreased by 6 or -13.33% compared to the same quarter last year.
Employees
39
Change
-6
Growth
-13.33%
Revenue / Employee
n/a
Profits / Employee
-$1,867,718
Market Cap
31.15M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 39 | -6 | -13.33% |
| Jun 30, 2025 | 46 | 1 | 2.22% |
| Mar 31, 2025 | 46 | 0 | - |
| Dec 31, 2024 | 46 | -1 | -2.13% |
| Sep 30, 2024 | 45 | -1 | -2.17% |
| Jun 30, 2024 | 45 | -3 | -6.25% |
| Mar 31, 2024 | 46 | 0 | - |
| Dec 31, 2023 | 47 | 1 | 2.17% |
| Sep 30, 2023 | 46 | -2 | -4.17% |
| Jun 30, 2023 | 48 | 1 | 2.13% |
| Mar 31, 2023 | 46 | 4 | 9.52% |
| Dec 31, 2022 | 46 | 7 | 17.95% |
| Sep 30, 2022 | 48 | 12 | 33.33% |
| Jun 30, 2022 | 47 | 16 | 51.61% |
| Mar 31, 2022 | 42 | 14 | 50.00% |
| Dec 31, 2021 | 39 | 15 | 62.50% |
| Sep 30, 2021 | 36 | 12 | 50.00% |
| Jun 30, 2021 | 31 | - | - |
| Mar 31, 2021 | 28 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Barinthus Biotherapeutics | 105 |
| AN2 Therapeutics | 22 |
| Outlook Therapeutics | 17 |
| NeuroSense Therapeutics | 17 |
| Skye Bioscience | 16 |
| Hyperion DeFi | 14 |
| Serina Therapeutics | 13 |
| Rein Therapeutics | 11 |
HOWL News
- 6 weeks ago - Werewolf Therapeutics Announces Pipeline and Business Updates - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - GlobeNewsWire
- 4 months ago - Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 5 months ago - Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 6 months ago - Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit - GlobeNewsWire